CLINICAL TRIAL II OF IROFULVEN EVERY TWO WEEKS IN PATIENTS WITH IRRESECABLE HEPATOCELLULAR CARCINOMA
- Conditions
- -C220 Liver cell carcinomaLiver cell carcinomaC220
- Registration Number
- PER-015-03
- Lead Sponsor
- MGI PHARMA, INC.,
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Not specified
- Target Recruitment
- 0
- The patient must sign the written informed consent approved by the institutional committee for scientific review (IRB).
- The patient must have a histological or cytological diagnosis of hepatocellular carcinoma that has been considered unresectable.
- The patient should not have more than one previous therapeutic intervention for the treatment of hepatocellular carcinoma including surgical techniques, ablative,
chemo-embolization, and systemic chemotherapy.
- Previous treatment with gene therapy.
- Women who are pregnant or breast-feeding.
- Patients with any concomitant systemic disorder (in the opinion of the researcher)
- Patients who have completed or who have been withdrawn from this study or any other study with irofulven.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method